Some other drug candidates targeting proteins encoded by BCC-associated loci are also currently under consideration in ongoing clinical trials45–47 for treating various cancer types and Cowden syndrome, including samotolisib, a PI3-kinase class I inhibitor targeting PIK3R1. Here, PIK3R1 is linked to Cowden disease.